简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。丁洋先生:中国国籍,博士研究生。曾任加州大学圣地亚哥分校博士后研究员;2017年12月1日加 入工银瑞信基金管理有限公司,现担任研究部基金经理助理、基金经理。2023年5月5日至今,担任工银瑞 信医疗保健行业股票型证券投资基金基金经理。 来源：金融界 金融界2025年7月30日消息，工银医疗保健股票(000831) 最新净值2.9710元，下跌0.74%。该基金近1个 月收益率13. ...

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received a notice of acceptance from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke [1] Company Summary - The application for Edaravone tablets, with the development code TTYP01, has been officially accepted by the NMPA [1] - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improve brain edema, tissue injury, and delay neuronal death [1] - The mechanism of Edaravone involves reacting with oxygen free radicals closely related to ischemic brain injury, providing protective effects against brain ischemic damage [1]

人民财讯7月30日电，华东医药（000963）7月30日晚间公告，公司全资子公司中美华东收到国家药品监 督管理局签发的《受理通知书》，由中美华东申报的依达拉奉片(研发代码：TTYP01)用于治疗急性缺 血性脑卒中的上市许可申请获得受理。依达拉奉是神经系统药物中的重磅品种，相对于院内给药14天的 依达拉奉注射液，依达拉奉口服片剂可以降低医药资源占用，适合患者自主长期给药。 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-077 华东医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年07月30日，华东医药股份有限公司（以下简称"公司"）全 资子公司杭州中美华东制药有限公司（以下简称"中美华东"）收到国 家药品监督管理局（NMPA）签发的《受理通知书》（受理号： CXHS2500088），由中美华东申报的依达拉奉片（研发代码： TTYP01）用于治疗急性缺血性脑卒中的上市许可申请获得受理。现 将有关详情公告如下： 一、该药物基本信息内容 药物名称：依达拉奉片 规格：30mg 申报适应症：改善急性缺血性脑卒中（Acute Ischemic Stroke, AIS） 所致的神经症状和功能障碍，提高日常生活能力。 申请人：杭州中美华东制药有限公司 结论：根据《中华人民共和国行政许可法》第三十二条的规定， 经审查，决定予以受理。 申请事项：境内生产药品注册上市许可 注册分类：化学药品2.2类 二、该药物研发及注册情况 第 1 页 共 3 页 依达拉奉是一种 ...

华东医药（000963）公告，全资子公司中美华东申报的依达拉奉片用于治疗急性缺血性脑卒中的上市许 可申请已获国家药品监督管理局受理。依达拉奉片是一种新型自由基清除剂，旨在改善脑卒中患者的神 经症状和功能障碍。与现有的依达拉奉注射液相比，该口服片剂更便于患者自行给药。中美华东已与澳 宗生物签署独家许可协议，获得该药在中国大陆及港澳台地区的开发、注册、生产及商业化权益。截至 目前，公司在该项目上已投入约1.01亿元，包括项目引进首付款1亿元。 ...

证券日报网讯华东医药（000963）7月29日在互动平台回答投资者提问时表示，公司深耕糖尿病治疗领 域，始终以差异化研发策略构建产品管线。中国糖尿病患者基数庞大且需求多元化，各机制产品存在互 补空间。公司产品定位、靶点机制及临床数据具备独特优势，将持续扎实推动临床进展与商业化布局。 ...

Group 1 - The company, Huadong Medicine, stated that its production and operations are currently normal [2] - There are no significant matters that should be disclosed but have not been disclosed [2]

Group 1 - The medical beauty market in China is experiencing continuous growth, with the number of compliant specialized medical beauty institutions reaching 19,880 in the first half of 2024, an increase of 1,296 institutions or 7% from January 2024 [1][3] - The increase in compliant medical beauty institutions is driven by enhanced regulatory oversight and a growing consumer demand for legitimate medical beauty services [1][3] Group 2 - There is a significant shortage of compliant medical beauty doctors, with an estimated gap of around 20,000 qualified professionals, while the total number of medical beauty practitioners is approximately 1.02 million [4] - The annual growth rate of medical beauty practitioners is around 10%, but the supply of qualified professionals is only increasing at a rate of 5%-8%, highlighting a supply-demand imbalance [4] Group 3 - The distribution of medical beauty positions in China shows a clear imbalance, with only 10% of positions being medical technical roles, which require solid medical knowledge and qualifications [6] - Over 60% of positions are in marketing and operations, which are crucial for attracting customers and driving business growth, but this focus may compromise the quality of medical services [6] Group 4 - The educational requirements for core positions in the medical beauty industry are increasing, with a trend towards higher educational qualifications among professionals [9] - Large medical beauty companies are setting stricter educational standards, with some requiring a full-time bachelor's degree for medical technical roles [9] Group 5 - The distribution of medical beauty talent in China shows a pattern of concentration in eastern regions and high-tier cities, with first-tier cities holding over 50% of medical beauty positions [10] - New first-tier cities are competing for mid-level talent through differentiated strategies, while lower-tier cities struggle due to a lack of local training capabilities [10]

Group 1: Company Performance - WuXi AppTec reported a net profit of 8.561 billion yuan for the first half of the year, a year-on-year increase of 101.92% [1] - The company's revenue for the first half reached 20.799 billion yuan, reflecting a growth of 20.64% year-on-year [1] - WuXi AppTec plans to distribute a cash dividend of 3.5 yuan per share to all shareholders [1] - The company has revised its revenue forecast for the full year to between 42.5 billion and 43.5 billion yuan [1] - SANY Heavy Industry plans to issue non-financial corporate debt financing tools not exceeding 20 billion yuan to optimize its financing structure [1] Group 2: Film Industry Impact - Happiness Blue Sea announced that the film "Nanjing Photo Studio" has surpassed 412 million yuan in cumulative box office, exceeding 50% of the company's audited revenue for the most recent fiscal year [2] - The film's impact on the company's revenue is currently negligible as it is still in theaters [2] Group 3: Corporate Actions - Zhonghua Equipment plans to issue shares to acquire 100% equity of two companies, marking a significant asset restructuring [2] - Dahua Intelligent is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [3] - Shiming Technology's actual controller and chairman has been placed under detention due to personal matters unrelated to the company [4] Group 4: Financial Performance - Ju Chen Co. reported a net profit growth of 43.5% for the first half of the year [6] - Qizheng Tibetan Medicine's net profit increased by 9.94% year-on-year [6] - China Minmetals' new contract value decreased by 19.1% year-on-year [6] - Huicheng Environmental's net profit declined by 85.63% year-on-year [6] Group 5: Mergers and Acquisitions - Kaishan Holdings plans to acquire a minority stake in SMGP for 3 million USD [6] - Zhonghua International intends to purchase 100% equity of Nantong Xingchen Composite Materials Co., Ltd. [6] - Xiangdian Co. plans to acquire a 12.5% stake in Tongda Electromagnetic Energy for 208 million yuan [6]

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of July 28, 2025, the latest net value of ICBC Frontier Medical Stock A is 3.4240 yuan, reflecting a growth of 3.04%. The fund's one-month return is 13.45%, six-month return is 32.00%, and year-to-date return is 30.14% [1] - The fund's top ten stock holdings account for a total of 59.44%, with significant investments in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and others [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan. The fund manager is Zhao Bei [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014 and currently holds multiple managerial positions within ICBC Credit Suisse Asset Management [2]